汇添富国证港股通创新药ETF发起式联接C(021031)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-812,752,077.28 |
-386,109,316.65 |
152,819,514.68 |
1,207,155.80 |
| 利息合计 |
1,176,125.12 |
1,701,122.52 |
407,103.12 |
101,696.96 |
| 其中：存款利息收入 |
1,176,125.12 |
1,701,122.52 |
407,103.12 |
101,696.96 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-230,373,173.31 |
216,343,055.81 |
28,842,504.69 |
1,628,908.95 |
| 其中：股票投资收益 |
- |
- |
- |
- |
| 基金投资收益 |
-230,967,005.33 |
215,860,641.31 |
28,838,690.99 |
1,628,908.95 |
| 债券投资收益 |
593,832.02 |
482,414.50 |
3,813.70 |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
- |
- |
- |
- |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-586,894,766.24 |
-613,983,422.91 |
121,370,867.47 |
-655,189.19 |
| 其他收入 |
3,339,737.15 |
9,829,927.93 |
2,199,039.40 |
131,739.08 |
| 费用 |
4,243,195.81 |
5,659,752.48 |
601,534.05 |
97,462.70 |
| 管理人报酬 |
639,001.59 |
729,145.90 |
77,488.31 |
15,748.09 |
| 基金托管费 |
127,800.32 |
145,829.18 |
15,497.68 |
3,149.68 |
| 销售服务费 |
3,401,899.10 |
3,742,787.71 |
327,188.70 |
57,685.12 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
783.06 |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
783.06 |
- |
- |
| 其他费用 |
74,383.76 |
150,400.00 |
77,263.46 |
15,000.00 |
| 利润总额 |
-816,995,273.09 |
-391,769,069.13 |
152,217,980.63 |
1,109,693.10 |
微信公众号
证券之星APP
基本资料
